Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05724173
Other study ID # 2022p003220 (BG-Speech-01)
Secondary ID U01DC019430
Status Recruiting
Phase N/A
First received
Last updated
Start date October 18, 2023
Est. completion date December 2026

Study information

Verified date October 2023
Source Massachusetts General Hospital
Contact Leigh R Hochberg, MD, Ph.D
Phone 617-724-9247
Email lhochberg@mgh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.


Description:

The goal of the BrainGate2 research and development project is to identify the core methods and features for a medical device that could allow people with paralysis, including severe speech impairment, to recover a host of abilities that normally rely on the hands or on speech.


Recruitment information / eligibility

Status Recruiting
Enrollment 2
Est. completion date December 2026
Est. primary completion date July 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Participants must have a diagnosis of amyotrophic lateral sclerosis (ALS) as verified by a clinical expert in neurologic diseases. - Participants with a diagnosis of ALS with anarthria, or severe dysarthria with decline in the preceding four months. Exclusion Criteria: 1. Between 18 and 80 years of age. 2. The patient must be able to speak understandably or if unable to speak understandably must have one reliable means of communication. 3. Complete or incomplete tetraplegia (quadriplegia) 4. A minimum of twelve months elapsed post-injury and recovery must have plateaued at least 3 months prior to baseline screening. 5. Per clinical opinion, a life expectancy of greater than 6 months. 6. Must be within a three-hour drive of the Study site and geographically stable for at least 15 months after enrollment. (There are additional exclusion criteria)

Study Design


Intervention

Device:
BrainGate Neural Interface System
Placement of the BrainGate2 sensor(s) into the speech-related cortex

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts
United States Stanford University School of Medicine Stanford California

Sponsors (2)

Lead Sponsor Collaborator
Leigh R. Hochberg, MD, PhD. National Institute on Deafness and Other Communication Disorders (NIDCD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Device Safety To determine the safety of the Sensor and overall safety of the System. Participants will be considered a success for this safety measure if they are successfully implanted with the Sensor(s) and:
the sensors are not explanted for safety reasons during the one-year post-implant evaluation period.
there are no device-related Serious Adverse Events that result in death or permanently increased disability during the one-year post-implant evaluation period.
1 year
Secondary Device Feasibility The purpose of this feasibility measure is to define the metrics by which a larger trial of intracortical recording for the restoration of speech-based communication might be planned.
The secondary endpoints are:
Number of participants that are able to use the BrainGate system to communicate via speech decoding:
at a rate of at least 5 words per minute and
with less than a median word error rate of 50%.
At participant exit from study, or up to 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06321172 - Muscle and Bone Changes After 6 Months of FES Cycling N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05484557 - Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury N/A
Suspended NCT05542238 - The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Not yet recruiting NCT05506657 - Early Intervention to Promote Return to Work for People With Spinal Cord Injury N/A
Recruiting NCT03680872 - Restoring Motor and Sensory Hand Function in Tetraplegia Using a Neural Bypass System N/A
Recruiting NCT04105114 - Transformation of Paralysis to Stepping Early Phase 1
Completed NCT04221373 - Exoskeletal-Assisted Walking in SCI Acute Inpatient Rehabilitation N/A
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Completed NCT03898700 - Coaching for Caregivers of Children With Spinal Cord Injury N/A
Recruiting NCT04883463 - Neuromodulation to Improve Respiratory Function in Cervical Spinal Cord Injury N/A
Active, not recruiting NCT04881565 - Losing Balance to Prevent Falls After Spinal Cord Injury (RBT+FES) N/A
Completed NCT04864262 - Photovoice for Spinal Cord Injury to Prevent Falls N/A
Recruiting NCT04007380 - Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI N/A
Active, not recruiting NCT04544761 - Resilience in Persons Following Spinal Cord Injury
Terminated NCT03170557 - Randomized Comparative Trial for Persistent Pain in Spinal Cord Injury: Acupuncture vs Aspecific Needle Skin Stimulation N/A
Completed NCT03220451 - Use of Adhesive Elastic Taping for the Therapy of Medium/Severe Pressure Ulcers in Spinal Cord Injured Patients N/A
Recruiting NCT04811235 - Optical Monitoring With Near-Infrared Spectroscopy for Spinal Cord Injury Trial N/A
Recruiting NCT04736849 - Epidural and Dorsal Root Stimulation in Humans With Spinal Cord Injury N/A